Company: AGIO
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001193125-25-096719
Chunk: 30

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 30
---
 corporate governance guidelines, as well as each of our committee charters, on the Corporate Governance page of the Investors section of our website, www.agios.com, which you can access free of charge. Information contained on the website is not incorporated by reference in, or considered part of, this Proxy Statement. We intend to disclose on our website any amendments to, or waivers from, our code of business conduct and ethics that are required to be disclosed by law or Nasdaq listing standards. We will also provide copies of these documents, as well as our other corporate governance documents, free of charge, to any stockholder upon written request to Investor Relations, at 88 Sidney Street, Cambridge, Massachusetts 02139; telephone: 617-649-8600; e-mail:IR@agios.com. Corporate Governance Guidelines Our board of directors has adopted corporate governance guidelines to assist in the exercise of its duties and responsibilities and to serve the best interests of Agios and our stockholders. These guidelines, which provide a framework for the conduct of our board’s business, provide that:

| • |     | our board’s principal responsibility is to oversee the management of Agios; |

| • |     | a majority of the members of our board shall be independent directors; |

| • |     | the independent directors meet regularly in executive session; |

| • |     | directors have full and free access to management and, as necessary and appropriate, independent advisors; |

| • |     | new directors participate in an orientation program and all directors are expected to participate in continuing director education on an ongoing basis; and |

| • |     | our board and its committees conduct a self-evaluation annually to determine whether they are functioning effectively. |

**Corporate Social Responsibility We are committed to building a sustainable business that provides long-term value for all our stakeholders. Central to our mission is our drive to improve the lives of patients with life-threatening and life-altering rare diseases, including those communities that have, until now, been underserved. We also support and advance a range of other responsibilities, such as: increasing access to medicines; furthering knowledge of rare conditions; promoting principles of inclusion inside and outside of the company; building a strong culture of flexibility and respect; supporting health equity; reducing our waste and energy usage; making a difference in our communities; and conducting our business according to the highest ethical standards. Since 2020, we have published our Environmental, Social, and Governance, or ESG, Report, with the intent of disclosing relevant E